Ftse Mib
33.315,68
1,24%
DAX
18.131,97
0,32%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
65.107,41
-0,04%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Silverback Therapeutics Inc (SBTX) Silverback Therapeutics Inc (SBTX) Notizie

SBTX

Silverback Therapeutics (SBTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SBTX
DataOraFonteTitoloSimboloCompagnia
28/06/202322:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
15/05/202315:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SBTXSilverback Therapeutics Inc
08/05/202322:35Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202322:42Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202322:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SBTXSilverback Therapeutics Inc
23/03/202321:14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SBTXSilverback Therapeutics Inc
23/02/202322:01GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle InjectorsNASDAQ:SBTXSilverback Therapeutics Inc
22/02/202322:05GlobeNewswire Inc.ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
13/02/202322:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SBTXSilverback Therapeutics Inc
09/02/202312:30GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202323:07Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202322:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202323:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
30/11/202222:24Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SBTXSilverback Therapeutics Inc
21/11/202222:08Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
10/11/202223:02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
10/11/202214:00GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
08/11/202222:02GlobeNewswire Inc.ARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics Inc
27/10/202222:17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SBTXSilverback Therapeutics Inc
21/10/202214:36Dow Jones NewsSilverback Therapeutics' Nasal Spray for Allergic Reactions Gets FDA Review ApprovalNASDAQ:SBTXSilverback Therapeutics Inc
21/10/202213:31Business WireSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
06/10/202222:17Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:SBTXSilverback Therapeutics Inc
11/08/202223:23Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:SBTXSilverback Therapeutics Inc
22/07/202212:15TipRanksAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV), Anixa Biosciences (ANIX) and Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
21/07/202222:00Business WireSilverback Therapeutics and ARS Pharmaceuticals Announce MergerNASDAQ:SBTXSilverback Therapeutics Inc
18/07/202212:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SBTXSilverback Therapeutics Inc
17/05/202222:05Business WireSilverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:SBTXSilverback Therapeutics Inc
15/05/202218:38TipRanksJonesTrading Keeps Their Hold Rating on Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
13/05/202214:49TipRanksH.C. Wainwright Keeps a Hold Rating on Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
12/05/202222:01Business WireSilverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:SBTXSilverback Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SBTX

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
MONC
Moncler
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
SPM
Saipem
BIT
LDO
Leonardo
BIT
RACE
Ferrari NV
BIT
A2A
A2A
BIT
SRG
Snam
BIT
BAMI
Banco BPM
BIT
TEN
Tenaris
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network